Rigel EVP & CFO has 3,546 shares withheld for taxes

Rigel Pharmaceuticals executive Dean L. Schorno reported a tax-related share disposition.

Rhea-AI Filing Summary

Rigel Pharmaceuticals executive Dean L. Schorno reported a tax-related share disposition. As EVP & Chief Financial Officer, he had 3,546 shares of Rigel Pharmaceuticals common stock withheld on February 10, 2026 to cover tax obligations at a price of $34.62 per share.

After this tax-withholding disposition, he directly beneficially owned 55,701 shares of Rigel Pharmaceuticals common stock. The filing characterizes the transaction as payment of a tax liability by delivering securities, rather than an open-market sale.

Insider Trade Summary

Exercise Price or Tax Liability: 3,546 shares

Exercise Price or Tax Liability 1 txn

Insider Schorno Dean L

Role EVP & Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	3,546	$34.62	$123K

Holdings After Transaction: Common Stock — 55,701 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Rigel Pharmaceuticals (RIGL) report for Dean L. Schorno?

Rigel Pharmaceuticals reported a Form 4 for EVP & CFO Dean L. Schorno showing 3,546 common shares withheld on February 10, 2026 to satisfy tax obligations, classified as payment of a tax liability by delivering securities, not an open-market sale.

How many Rigel Pharmaceuticals (RIGL) shares were involved in Dean Schorno’s 2026 Form 4?

The Form 4 shows 3,546 Rigel Pharmaceuticals common shares were disposed of on February 10, 2026. The transaction code “F” indicates the shares were used to pay a tax liability, with a reported transaction price of $34.62 per share for the withheld stock.

What is Dean L. Schorno’s remaining Rigel Pharmaceuticals (RIGL) share ownership?

After the February 10, 2026 tax-withholding transaction, EVP & CFO Dean L. Schorno directly beneficially owned 55,701 shares of Rigel Pharmaceuticals common stock. The Form 4 classifies this entire post-transaction position as direct ownership, with no indirect ownership reported in the filing.

Was the Rigel Pharmaceuticals (RIGL) insider transaction a market sale?

The transaction was not reported as a market sale. The Form 4 uses transaction code “F,” defined as payment of an exercise price or tax liability by delivering securities, meaning 3,546 shares were withheld to cover taxes rather than sold on the open market.

What role does Dean L. Schorno hold at Rigel Pharmaceuticals (RIGL)?

Dean L. Schorno is identified as an officer of Rigel Pharmaceuticals, serving as Executive Vice President & Chief Financial Officer. The Form 4 confirms his status as an officer, not a director or 10% owner, when reporting the February 10, 2026 tax-withholding share disposition.

At what price were Dean Schorno’s Rigel Pharmaceuticals (RIGL) shares valued for tax withholding?

The 3,546 Rigel Pharmaceuticals common shares used for tax withholding on February 10, 2026 were reported at $34.62 per share. This per-share amount reflects the value used in the filing for the tax-liability payment transaction recorded under code “F.”

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 04:50 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schorno Dean L

(Last) (First) (Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		F		3,546	D	$34.62	55,701	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Raymond Furey (Attorney-in-Fact)	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.